Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
HealthLeaders-InterStudy and Fingertip Formulary find that Amylin's Byetta has better formulary positioning than Novo Nordisk's Victoza for the treatment of Type 2 Diabetes. The drugs have similar provider plan beneficiaries but more lives have access to Byetta on advantaged tiers and without restrictions, according to a new report entitled Formulary Advantages in Type 2 Diabetes.
Eighty-five percent of private lives have access to Byetta on advantaged tiers, while only 40 percent of private lives have similar access to Victoza, according to the report.
http://www.marketwatch.com/story/am...toza-for-type-2-diabetes-treatment-2011-12-05
Eighty-five percent of private lives have access to Byetta on advantaged tiers, while only 40 percent of private lives have similar access to Victoza, according to the report.
http://www.marketwatch.com/story/am...toza-for-type-2-diabetes-treatment-2011-12-05